Mirum Pharmaceuticals Inc. (MIRM)

Trade MIRM now with
8/9/2022 9:39:09 PM Mirum Pharmaceuticals Prices Underwritten Public Offering Of 3.48 Mln Shares At $23.00/shr
7/8/2022 9:02:47 PM Mirum Pharmaceuticals Reports Inducement Grants
6/24/2022 8:07:47 AM Mirum Pharma Highlights Data Demonstrating Impact Of LIVMARLI on Patients With Alagille Syndrome
6/24/2022 3:13:26 AM Mirum Pharma Presents New Data At The International Liver Congress EASL
5/23/2022 8:36:59 AM Mirum Pharma Acquires Satiogen Pharma
5/5/2022 8:12:21 AM Mirum Pharma Q1 Net Loss Of $36.6 Mln Or $1.17/shr Vs Net Loss Of $50.5 Mln Or $1.68/shr Prior Year
3/10/2022 11:30:46 PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/10/2022 8:50:05 PM Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule
12/13/2021 8:41:24 AM Mirum : LIVMARLI Presentations Show Improvements In Quality Of Life Measures In Alagille Syndrome And PFIC2
12/6/2021 8:37:45 AM Mirum Pharma To Present LIVMARLI Analyses At NASPGHAN 2021 Annual Meeting
11/17/2021 8:36:20 AM Mirum Pharmaceuticals To Sell Its Rare Pediatric Disease Priority Review Voucher For $110 Mln
11/15/2021 4:11:55 PM Mirum Pharma Q3 Loss/share $1.55 Vs. Loss $0.86 Year Ago
11/1/2021 8:39:16 AM Lancet Publishes Data From Mirum Pharma' ICONIC Pivotal Study Of Maralixibat Treatment In Alagille Syndrome
9/21/2021 8:04:37 AM Mirum Pharma And Takeda Enter Licensing Deal To Develop Maralixibat For Rare Pediatric Liver Diseases In Japan
9/13/2021 6:47:46 AM Mirum Pharma Submits MAA For Cholestatic Liver Disease In Patients With Alagille Syndrome To EMA
7/26/2021 9:37:17 PM Mirum Pharma And GC Pharma To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea